
07/09/2025
The Difference Between Semaglutide and Tirzepatide
Many patients ask about the differences between the two primary GLP-1 medications we offer. Here's what the research shows:
Semaglutide (comparable to Ozempic/Wegovy):
☑️ Works specifically on GLP-1 receptors
☑️Typically leads to 15-20% total body weight loss over 68 weeks
☑️Well-established safety profile with years of clinical data
☑️Weekly injection or our new oral drop formulation
☑️Often the first choice for many patients
Tirzepatide (comparable to Mounjaro):
☑️Works on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors
☑️May produce slightly greater weight loss (approximately 20-25% in clinical trials)
☑️Newer to market with strong but less extensive long-term data
☑️Also available as weekly injection or oral drops
☑️May be particularly effective for patients with insulin resistance